双鹭药业(002038) - 2020 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 27.18% to ¥106,455,925.09 for the reporting period[9] - Operating revenue for the reporting period was ¥305,275,969.73, a decrease of 41.91% year-on-year[9] - Basic earnings per share decreased by 27.13% to ¥0.1037 for the reporting period[9] - The weighted average return on equity decreased by 1.36% to 2.19%[9] - Operating revenue decreased by 46.54% year-to-date compared to the same period last year, mainly due to the impact of the pandemic and the removal of key products from the medical insurance catalog, leading to a reduction in sales orders.[23] - The net profit for the current period is CNY 302,211,357.14, a decline of 39.1% from CNY 495,664,007.54 in the previous period[80] - The total comprehensive income for the current period is CNY 308,351,409.63, down from CNY 486,927,957.80 in the previous period[84] Assets and Liabilities - Total assets increased by 1.89% to ¥5,323,527,524.16 compared to the end of the previous year[9] - As of September 30, 2020, current assets totaled approximately ¥2.17 billion, a decrease of 24.2% from ¥2.87 billion on December 31, 2019[43] - The company's total equity increased to approximately ¥4.92 billion from ¥4.82 billion, a growth of 2.1%[52] - Current liabilities decreased to approximately ¥312 million from ¥333 million, a decline of 6.4%[49] - Non-current liabilities totaled approximately ¥86.8 million, an increase from ¥71.1 million, indicating a rise of 22.1%[49] Cash Flow - The net cash flow from operating activities increased by 14.90% to ¥130,216,168.91 compared to the previous period[9] - Cash and cash equivalents decreased to approximately ¥528 million from ¥1.26 billion, representing a decline of 58.1%[43] - Cash flow from operating activities generated a net amount of ¥190,410,390.49, down 58.8% from ¥462,953,174.97 in the previous period[94] - Cash outflow from financing activities was $205,470,000.00, consistent with the previous period[103] Investments - Long-term equity investments increased by 126.32% compared to the beginning of the period, primarily due to new investments in Beijing Guoke New Mile Medical Health Technology Co., Ltd.[23] - The company reported an investment income of CNY 22,107,691.74, significantly higher than CNY 7,373,183.70 in the previous period, marking an increase of approximately 200%[62] - The company reported a fair value change gain of 28,692,801.65 yuan from securities investments during the reporting period.[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 55,155[14] - The largest shareholder, Xu Mingbo, holds 22.58% of the shares, totaling 231,990,007 shares[14] - The company did not engage in any repurchase transactions among the top ten shareholders during the reporting period[18] Research and Development - Research and development expenses decreased to CNY 19,967,762.60 from CNY 36,602,802.69, representing a reduction of about 45%[62] - Research and development expenses increased to ¥102,910,136.73, up 16.2% from ¥88,589,486.44 in the previous period[88] Other Financial Metrics - The company received government subsidies amounting to ¥11,615,243.86 during the reporting period[9] - The company has no overdue commitments from actual controllers, shareholders, related parties, acquirers, or other parties during the reporting period.[24] - The company has not engaged in derivative investments during the reporting period.[32] - The company has no violations regarding external guarantees during the reporting period.[35]